Table 6.
Height of Patients Stratified by Type of Drugs at Different Times from Enrolment
| MPH n | Mean±SD (cm) | ATX n | Mean±SD (cm) | MPH vs ATX t testa | |
|---|---|---|---|---|---|
| 0 months | 288 | 140.90±15.12 | 286 | 143.02±17.01 | |
| 6 months | 143.82±15.22 | 145.66±17.04 | |||
| 0 vs 6 mo. t testb | t287=21.36 | t285=17.87 | t572=1.36 | ||
| p<0.001 | p<0.001 | p=0.176 | |||
| 0 months | 167 | 141.22±15.50 | 139 | 144.01±16.89 | |
| 12 months | 146.23±15.73 | 148.10±17.00 | |||
| 0 vs 12 mo. t testb | t166=23.34 | t138=17.25 | t304=2.87 | ||
| p<0.001 | p<0.001 | p=0.004 | |||
| 0 months | 55 | 140.45±14.49 | 35 | 145.49±17.57 | |
| 24 months | 150.93±15.04 | 153.80±18.18 | |||
| 0 vs 24 mo. t testb | t54=16.08 | t34=9.26 | t88=1.99 | ||
| p<0.001 | p<0.001 | p=0.050 |
Heights are reported as means±standard deviations in cm.
a
Unpaired Student's t test: Comparisons between MPH and ATX-treated subjects regarding weight changes between baseline and the end of the specific reference period.
b
Paired Student's t test: Comparisons between measurements taken at baseline and at the end of the specific reference period, within each treatment group.
MPH, methylphenidate; ATX, atomoxetine; df, degrees of freedom.